San Diego, CA · Founded 2011 · Privately Held (backing)
Developer of a small molecule therapeutics platform designed to reprogram protein folding for the treatment of various systemic amyloid diseases and protein misfolding diseases. Protego Biopharma is based in San Diego, CA and was founded in 2011. Its last reported valuation was $217 million in Mar 2025. It has raised $182 million across 3 recorded rounds; the latest was a $32.9 million early-stage round in Oct 2025.
Last reported valuation
$216.5M
Oct 2026
Priced at
—
Total raised
$182.1M
Last round
Early Stage VC
Oct 2025
Cap table — not yet on record
Protego Biopharma's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Protego Biopharma with a free account
·The complete investor list: 12 names
·Watch Protego Biopharma: the Monday email on marks, rounds and moves
Where does Protego Biopharma's cap table come from?
Share classes are assembled from certificates of incorporation, priced-round filings, and disclosures across Protego Biopharma's 3 recorded funding rounds.
